Skip to main content
Premium Trial:

Request an Annual Quote

Mireven Secures Additional Funding

Premium

Australian microRNA drug developer Mireven said last week that it has received an additional A$500,000 ($511,000) from early-stage investment group Medical Research Commercialization Fund, bringing the total investment MRCF has made in the company to A$1.1 million.

According to Mireven, the additional investment is the result of its achievement of undisclosed technical and commercial milestones. The company is developing a mimic of miR-7 as a treatment for cancer.

“This pivotal funding from the MRCF allows Mireven to expand and undertake in vivo studies to examine the delivery of miR-7 with independent parties,” Mireven Chairman Stephen Thompson said in a statement.

Last month, Mireven signed a deal to evaluate Silence Therapeutics' delivery technologies with its miR-7 mimetic (GSN 8/23/2012). It said that it has also inked a second deal with an undisclosed “international company” focused on “positioning miR-7 as a cancer therapeutic.”

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.